Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00323284
Other study ID # GC-003
Secondary ID
Status Completed
Phase Phase 3
First received May 6, 2006
Last updated December 14, 2017
Start date June 2005
Est. completion date March 2010

Study information

Verified date March 2016
Source Glaukos Corporation
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the safety and efficacy of the iStent trabecular micro-bypass stent in reducing intraocular pressure (IOP) in subjects with open-angle glaucoma or ocular hypertension and co-existing cataract.


Description:

The purpose of this study is to evaluate the safety and efficacy of the iStent trabecular micro-bypass stent in reducing intraocular pressure (IOP) in subjects with open-angle glaucoma or ocular hypertension and co-existing cataract. Pre-operative unmedicated baseline pressures will be compared with post operative values in both study arms.


Recruitment information / eligibility

Status Completed
Enrollment 240
Est. completion date March 2010
Est. primary completion date July 2009
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Diagnosed with open-angle glaucoma (OAG) in the study eye. Pseudoexfoliative and pigmentary glaucoma are also acceptable diagnoses.

- Subject on at least one glaucoma medication

- Able and willing to attend follow up visits for two years post operative

- Able and willing to sign informed consent

Exclusion Criteria:

- Prior glaucoma procedures (eg trabeculectomy, viscocanalostomy, ALT, SLT, shunt implant, collagen implant, cyclo destructive procedures etc)

- Angle closure glaucoma

- Fellow eye already enrolled

Study Design


Related Conditions & MeSH terms


Intervention

Device:
iStent plus Cataract Surgery
ab interno trabecular bypass stent surgery
Procedure:
Cataract surgery only
Cataract surgery only

Locations

Country Name City State
United States Williamson Nelson Eye Center Baton Rouge Louisiana
United States Southeast Texas Medical Association, L.L.P. Beaumont Texas
United States Assil Eye Institute Beverly Hills California
United States Florida Eye Microsurgical Institute, Inc. Boynton Beach Florida
United States Laurel Eye Center Brookville Pennsylvania
United States Cinicinnati Eye Institute Cincinnati Ohio
United States Kresge Eye Institute Detroit Michigan
United States Chu Vision Institute Edina Minnesota
United States Donald J. Digby and Associates Greensboro North Carolina
United States Discover Vision Centers Independence Missouri
United States Indiana University Indianapolis Indiana
United States Silverstein Eye Centers Kansas City Missouri
United States The Shepherd Eye Center Las Vegas Nevada
United States Glaucoma Consultants of Colorado Littleton Colorado
United States The Eye Care Institute Building Louisville Kentucky
United States The Center for Excellence in Eye Care Miami Florida
United States University of Minnesota Minneapolis Minnesota
United States Clayton Eye Center Morrow Georgia
United States Stiles Eyecare Excellence Overland Park Kansas
United States North Bay Eye Associates Inc Petaluma California
United States Wills Eye Hospital Philadelphia Pennsylvania
United States Associates in Ophthalmology Pittsburgh Pennsylvania
United States UPMC Eye Center Pittsburgh Pennsylvania
United States Mayo Clinic Rochester Minnesota
United States Ellison Ambulatory Care Center Sacramento California
United States Great Lakes Eye Care Saint Joseph Michigan
United States Harvard Eye Associates San Clemente California
United States Shepard Eye Center Santa Maria California
United States Glaucoma Consultants of Capital Region Slingerlands New York
United States International Eye Center Tampa Florida
United States James Branch MD Winston-Salem North Carolina

Sponsors (1)

Lead Sponsor Collaborator
Glaukos Corporation

Country where clinical trial is conducted

United States, 

References & Publications (2)

Craven ER, Katz LJ, Wells JM, Giamporcaro JE; iStent Study Group. Cataract surgery with trabecular micro-bypass stent implantation in patients with mild-to-moderate open-angle glaucoma and cataract: two-year follow-up. J Cataract Refract Surg. 2012 Aug;38 — View Citation

Samuelson TW, Katz LJ, Wells JM, Duh YJ, Giamporcaro JE; US iStent Study Group. Randomized evaluation of the trabecular micro-bypass stent with phacoemulsification in patients with glaucoma and cataract. Ophthalmology. 2011 Mar;118(3):459-67. doi: 10.1016 — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Intraocular Pressure (Measured in mm Hg) Less or Equal to 21 mm Hg on no Topical Hypotensive Meds Subjects with an intraocular pressure (IOP) less than or equal to 21 mm Hg without use of topical hypotensive medication at 12 months 12 months
Secondary Efficacy Subjects with an intraocular pressure (IOP) reduction from baseline of greater than or equal to 20% without use of topical hypotensive medication at 12 months 12 months
See also
  Status Clinical Trial Phase
Completed NCT01157364 - Safety and Efficacy of a New Ophthalmic Formulation of Bimatoprost in Patients With Open Angle Glaucoma and Ocular Hypertension Phase 1/Phase 2
Completed NCT02558374 - Double-masked Study of Netarsudil (AR-13324) Ophthalmic Solution in Subjects With Glaucoma or Ocular Hypertension Phase 3
Completed NCT01340014 - Patient Preference Comparison of AZARGA Versus COSOPT Phase 4
Completed NCT01444105 - Open-angle Glaucoma Subjects on One Ocular Hypotensive Medication Randomized to Treatment With Two Trabecular Micro-bypass Stents or Selective Laser Trabeculoplasty N/A
Completed NCT01456390 - Open-Angle Glaucoma Subjects With One Prior Trabeculectomy Treated Concurrently With One Suprachoroidal Stent and Two Trabecular Micro-bypass Stents N/A
Completed NCT01444040 - Subjects With Open-angle Glaucoma, Pseudoexfoliative Glaucoma, or Ocular Hypertension Naïve to Medical and Surgical Therapy, Treated With Two Trabecular Micro-bypass Stents (iStent Inject) or Travoprost Phase 4
Completed NCT01443988 - Subjects With Open-angle Glaucoma, Pseudoexfoliative Glaucoma, or Ocular Hypertension Naïve to Medical and Surgical Therapy, Treated With Two Trabecular Micro-bypass Stents (iStent)or Travoprost Phase 4
Completed NCT01455467 - Open-angle Glaucoma Subjects on One Topical Hypotensive Medication Randomized to Treatment With One or Two Trabecular Micro-bypass Stents in Conjunction With Cataract Surgery N/A
Completed NCT01415401 - Efficacy and Tolerability of AZARGA® as Replacement Therapy in Patients on COMBIGAN® Therapy in Canada Phase 4
Completed NCT01487655 - Waveform Analysis of the Doppler Curve of Ophthalmic Arteries in Glaucoma Patients N/A
Completed NCT01426867 - A Comfort Study of Brinzolamide 1% / Brimonidine 0.2% Fixed Combination, Brinzolamide 1% and Brimonidine 0.2% Phase 2
Completed NCT00759239 - Phase IV Randomised Double-masked Clinical Trial: Assessing Morning Versus Evening Dosing of a Fixed Dose Combination of Travoprost 0.004% / Timolol Maleate 0.5% in Patients With Primary Open-angle Glaucoma or Ocular Hypertension Phase 4
Completed NCT00397241 - 24-hour Study of Dorzolamide/Timolol and Latanoprost/Timolol Fixed Combinations Phase 4
Completed NCT00273481 - Cosopt Versus Xalacom Phase 4
Completed NCT00918346 - Pharmacodynamics of Tafluprost 0.0015% Eye Drops: a Comparison Between the Preserved and Unpreserved Formulation Phase 3
Completed NCT00716742 - Safety and Efficacy Study of Bimatoprost, Latanoprost, and Travoprost in Patients With Elevated Intraocular Pressure (IOP) and Open-angle Glaucoma (OAG) N/A
Completed NCT02558400 - Double-masked Study of PG324 Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension Phase 3
Withdrawn NCT03648229 - African Glaucoma Laser Trial Phase 4
Completed NCT01978600 - Evaluation of Intraocular Pressure Using Simbrinza™ in Patients With Open-Angle Glaucoma or Ocular Hypertension Phase 4
Completed NCT01699464 - A Study Assessing the Safety and Ocular Hypotensive Efficacy of AR-12286 in Patients With Elevated Intraocular Pressure for 3 Months Phase 2